#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA4028573	B	Inhibition of human ACMSD expressed in Pichia pastoris using ACMS as substrate by coupled spectrophotometric assay	Homo sapiens	13	ALA4024800	assay format	Scientific Literature
2.	ALA4028574	B	Inhibition of ACMSD in human primary hepatocytes assessed as increase in intracellular NAD+ levels at 5 uM after 48 hrs by NAD/NADH-Glo assay	Homo sapiens	2	ALA4024800	cell-based format	Scientific Literature
3.	ALA4418029	B	Inhibition of human recombinant ACMSD1 expressed in Escherichia coli BL21 (DE3) cells assessed as reduction in conversion of 3-OH-anthranilic acid into ACMS by spectrophotometry	Homo sapiens	22	ALA4417632	cell-based format	Patent Bioactivity Data
4.	ALA4418030	B	Inhibition of human recombinant ACMSD1 expressed in HEK293T cells assessed as reduction in conversion of 3-OH-anthranilic acid into ACMS by spectrophotometry	Homo sapiens	1	ALA4417632	cell-based format	Patent Bioactivity Data
5.	ALA4418031	B	Inhibition of ACMSD in human primary hepatocytes assessed as increase in NAD concentration at 0.5 uM following compound replacement every 24 hrs by LC-MS/MS analysis	Homo sapiens	2	ALA4417632	cell-based format	Patent Bioactivity Data
6.	ALA4418032	B	Inhibition of ACMSD in human primary hepatocytes assessed as increase in NAD concentration at 5 uM following compound replacement every 24 hrs by LC-MS/MS analysis	Homo sapiens	1	ALA4417632	cell-based format	Patent Bioactivity Data
7.	ALA4418033	B	Inhibition of ACMSD in human primary hepatocytes assessed as increase in NAD concentration at 500 uM following compound replacement every 24 hrs by LC-MS/MS analysis relative to control	Homo sapiens	1	ALA4417632	cell-based format	Patent Bioactivity Data
8.	ALA4418034	B	Inhibition of ACMSD in human primary hepatocytes assessed as increase in NAD concentration at 250 uM following compound replacement every 24 hrs by LC-MS/MS analysis	Homo sapiens	1	ALA4417632	cell-based format	Patent Bioactivity Data
9.	ALA4418037	B	Inhibition of ACMSD in human primary hepatocytes assessed as increase in NAD\"\" concentration following compound replacement every 24 hrs by LC-MS/MS analysis relative to control	Homo sapiens	1	ALA4417632	cell-based format	Patent Bioactivity Data
10.	ALA4418042	B	Inhibition of ACMSD in in human Hepa1-6 cells assessed as increase in Sod2 mRNA expression incubated for 24 hrs by RT-qPCR analysis	Homo sapiens	1	ALA4417632	cell-based format	Patent Bioactivity Data
11.	ALA4420580	B	Inhibition of human recombinant ACMSD1 expressed in Escherichia coli BL21 (DE3) cells assessed as reduction in conversion of 3-OH-anthranilic acid into ACMS by spectrophotometry	Homo sapiens	15	ALA4420067	cell-based format	Patent Bioactivity Data
12.	ALA4775521	B	Inhibition of human ACMSD assessed as QUIN level at 1 mM by HPLC analysis (Rvb = 16.4 +/- 2.9%)	Homo sapiens	26	ALA4765479	single protein format	Scientific Literature
13.	ALA4775522	B	Inhibition of human ACMSD assessed as picolinic acid level at 1 mM by HPLC analysis (Rvb = 83.6 +/- 3.1%)	Homo sapiens	26	ALA4765479	single protein format	Scientific Literature
14.	ALA4775523	B	Inhibition of ACMSD (unknown origin)	Homo sapiens	2	ALA4765479	single protein format	Scientific Literature
15.	ALA4775524	B	Competitive inhibition of human ACMSD using ACMS substrate by spectrometry	Homo sapiens	2	ALA4765479	single protein format	Scientific Literature
16.	ALA4775525	B	Inhibition of human ACMSD using ACMS substrate by spectrometry	Homo sapiens	16	ALA4765479	single protein format	Scientific Literature
17.	ALA4775526	B	Inhibition of human ACMSD in presence of 10 uM 3-HAA by coupled assay	Homo sapiens	1	ALA4765479	single protein format	Scientific Literature